multipurpose prevention technologies what are they & why do we need them?

Multipurpose Prevention TechnologiesWhat are they & why do we need them?[Presenter name, degree, affiliation][Event title]

[Date]

Multipurpose Prevention Technologies for Reproductive Health

What do women want and need?

Every year. . . 80 million unintended pregnancies 358,000 women die from pregnancy- related complications

2.5 million people infected with HIV 340 million new gonorrhea, syphilis, trichomonas infections

250,000 deaths from cervical cancer 16 % (15-49) have genital herpes (HSV-2)

products that… Prevent pregnancy,

HIV/AIDS & STIs at the same time

Ensure women’s privacy and safety

Are affordable & easily available

Are designed by women for their specific needs & preferences

Imagine

Multipurpose Prevention Technologies

The Challenge

50 years of contraceptive advances

Sheldon SegalFirst long term

drug delivery deviceNorplant

;Female-controlled MPTs

Female Condom

SILCS Diaphragm

Women’s Condom

Currently available MPTs

Female Condom Male Condom

Emerging MPTs

Drug combinations

Multipurpose vaccines

Drug/device combinations

Bacterial therapeutics

Nanoparticals

Potential Delivery Mechanisms for MPTs Devices

SILCS Diaphragm Women’s Condom

Vaginal Rings Drug release rates differ by ring type Matrix rings vs. Reservoir rings Release rates differ in-vitro from in-vivo

Vaginal Tablet Combining different class ART

Vaginal Film Nontoxic to cells and flora, fast dissolution

Multipurpose Vaccines: the future Today: Single purpose vaccines (HPV &

HBV) are commercially available Next 2 decades: Dual-purpose vaccines

that prevent transmission of HSV, HIV, Gonorrhea, Chlamydia, Trichomonas or other STIs

Contraceptive vaccines not likely

Collaboration, advocacy, & research to advance MPTs

Initiative on MPTs: Partner Organizations

MPTs in the Pipeline

Mapping Matrix: www.cami-health.org

CAMI Activities MPT Think Tank (May 2011) Target Product Profile working groups (May – Oct

2011) ARHP Conference (September 2011) APHA Conference (October 2011) International MPT Symposium, DC (November

2011) International MPT Symposium, London (January

2012) Microbicides 2012 Conference, Sydney (April 2012) NEXT STEPS

Future directions and priorities

Support and coordinate novel approaches for multi-disciplinary collaboration

Facilitate funding for research & development

Expand global and US support Refine priority Product Profiles Assist with clarifying the regulatory

pathways

Questions?www.cami-health.orgwww.arhp.orgwww.phi.org